FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Anthropic Introduces AI Agents for Financial Services Tasks

By

-- Amazon-backed (AMZN) Anthropic introduced new artificial intelligence agents built for a broader mix of financial services tasks, Bloomberg reported Tuesday.

These agents can draft pitch decks for client meetings, review financial statements, and escalate cases for compliance review, the report said, adding that they are designed for professionals in the banking, insurance, asset management and fintech industries.

Anthropic is also improving Claude AI's ability to work across third-party software like Excel, PowerPoint and Outlook, and integrate data from partners in the financial services industry, Bloomberg said.

Anthropic did not immediately respond to a request for comment by.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: $276.16, Change: $+4.08, Percent Change: +1.50%

Related Articles

Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Posco Holdings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our target price to USD94 from USD70, valuing POSCO at 0.66x 2026 P/BV, above its three-year mean of 0.52x. Our neutral view reflects: (i) recovering steel fundamentals supported by China's 2025 crude steel output declining 4.4% Y/Y and South Korea's anti-dumping duties on Chinese steel, which provides a pricing moat for Posco; and (ii) lithium market recovery with prices surging 49% YTD through April, supporting POSCO's battery materials segment which narrowed Q1 2026 losses significantly. POSCO's Australian and Argentine lithium acquisitions bolster its battery materials growth strategy. Additionally, the new Mid-term Shareholder Return Policy (2026-2028) targeting a 35%-40% payout ratio demonstrates commitment to shareholder value. However, risks include an aggressive 61% capex increase to KRW11.3 trillion in 2026, execution challenges on international projects, and persistent margin pressures. We adjust our 2026 EPS estimate to KRW6,379 from KRW5,932 and 2027 to KRW8,036 from KRW7,820.

$PKX
Research

Propel Holdings Maintained at Buy at Stifel Canada After Q1 Results; Price Target Kept at C$32.00

Stifel Canada on Tuesday reiterated its buy rating on the shares of Propel Holdings (PRL.TO) and its C$32.00 price target following the company's first-quarter results."Propel reported an upside FQ1, underscoring strength in loan growth alongside stable credit performance, on the back of the rebound in credit quality and subsequent new origination activity we saw exiting last quarter. Importantly, credit metrics PCLs and net-charge-offs normalized this quarter, supporting a recovery in ROE and fueling yet another bump in Propel's quarterly dividend (11th consecutive raise at +6.7% to $0.24/share). Net/net - results further reinforce resilience in the non-prime consumer backdrop, in-line with recent prints from US consumer credit peers. FY guide is being maintained, reaffirming the growth trajectory ahead, while suggesting some conservatism amidst the current macro uncertainty. Conference call tomorrow at 8:30am ET (dial-in: 1-888-699-1199/webcast). Our key focus on the call will be around (1) outlook for US consumer credit quality, (2) growth outlook for LaaS, (3) pace/scale of ongoing growth investments to support US expansion/Propel Bank launch," analyst Suthan Sukumar wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $24.15, Change: $+2.25, Percent Change: +10.27%

$PRL.TO
Australia

Correction: BioNTech Q1 Adjusted Loss Widens, Revenue Declines; Reaffirms 2026 Revenue Outlook

(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%

$BNTX